Related Experiment Videos
Indisulam: an anticancer sulfonamide in clinical development
1Università degli Studi di Firenze, Dipartimento di Chimica, Laboratorio di Chimica Bioinorganica, Via della Lastruccia, 3, Rm. 188, I-50019 Sesto Fiorentino, Florence, Italy. claudiu.supuran@unifi.it
Expert Opinion on Investigational Drugs
|January 31, 2003
Summary
Indisulam (E7070) is a novel anticancer drug showing promise for solid tumors. It works by stopping cell division, inhibiting carbonic anhydrase, and altering gene expression, with promising Phase I and ongoing Phase II trial results.
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- Indisulam (E7070) is a novel sulfonamide anticancer agent.
- It is currently in clinical development for solid tumors.
Purpose of the Study:
- To investigate the multifactorial mechanism of action of indisulam.
- To summarize promising results from Phase I clinical trials and ongoing Phase II trials.
Main Methods:
- The study describes the mechanism of action including cell cycle arrest, carbonic anhydrase inhibition, and gene expression alterations.
- Clinical trial data from Phase I and Phase II studies are referenced.
Main Results:
- Indisulam arrests the cell cycle in the G1 phase.
- It strongly inhibits carbonic anhydrase, an enzyme increasingly linked to cancer.
- Significant alterations in gene expression (at least 60 transcripts) were observed.
- Phase I trials indicated nonlinear pharmacokinetics and promising safety/efficacy signals.
Conclusions:
- Indisulam exhibits a multifactorial mechanism of action relevant to cancer treatment.
- The compound has shown promising results in early-phase clinical trials.
- Indisulam is advancing to Phase II trials for solid tumors in Europe and the USA.